Investing.com - H.C. Wainwright reiterated a Buy rating and $34.00 price target on Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX). The target aligns with the analyst high estimate, while the stock has delivered a remarkable 150% return over the past year despite recent volatility that saw shares close at $13.32.
The firm hosted a breakfast with two Post Bariatric Hypoglycemia physicians at the American Diabetes Association 2026 conference in New Orleans. The event focused on understanding what a clinically significant LUCIDITY readout might look like, assessing design risk in the trial, and evaluating the PBH unmet need and disease severity.
The physicians said a statistically significant effect size of even a 20% reduction in event rate would be encouraging given the absence of any targeted, disease-modifying therapy for the condition. Both endorsed the composite Level 2/Level 3 endpoint and validated the severity-enrichment design.
The physicians identified dietary liberalization over 16 weeks as the primary risk but do not expect efficacy to fade significantly. They pointed to quality of life and time-course data as equally important measures.
The physicians described PBH as a severe, underdiagnosed, untreated disease with a larger at-risk pool than the 160,000 patient estimate implies.According to InvestingPro analysis, Amylyx maintains a strong balance sheet with more cash than debt and liquid assets exceeding short-term obligations—critical for a clinical-stage biotech. The company’s Financial Health score rates as "Fair," with investors able to access deeper insights through comprehensive Pro Research Reports available for AMLX and 1,400+ other US equities.
In other recent news, Amylyx Pharmaceuticals Inc. reported a first-quarter 2026 loss per share of $0.37, which did not meet analysts’ expectations of a $0.33 loss per share. This shortfall in earnings was accompanied by increased operating expenses. Additionally, Amylyx announced that results from its Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome have been published in The Journal of Clinical Investigation. The trial, which involved 12 adults, showed continued improvements in pancreatic beta cell function through Week 48. These developments have been closely watched by investors and analysts alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.